Atossa Therapeutics Inc logo

Atossa Therapeutics Inc

FRA:YAG2 (USA)  
€ 1.22 (-0.81%) Sep 27
At Loss
P/B:
2.37
Market Cap:
€ 169.90M ($ 190.25M)
Enterprise V:
€ 98.75M ($ 110.58M)
Volume:
1.50K
Avg Vol (2M):
4.06K
Trade In:
Volume:
1.50K
At Loss

Business Description

Description
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.93
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 37.88
9-Day RSI 44.78
14-Day RSI 48.52
6-1 Month Momentum % -21.22
12-1 Month Momentum % 80.73

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 14.35
Quick Ratio 14.35
Cash Ratio 13.96

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -38.1